These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 17213264)

  • 21. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.
    Scheetz MH; Qi C; Warren JR; Postelnick MJ; Zembower T; Obias A; Noskin GA
    Antimicrob Agents Chemother; 2007 May; 51(5):1621-6. PubMed ID: 17307973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Colistin and tigecycline susceptibility among multidrug-resistant Acinetobacter baumannii isolated from ventilator-associated pneumonia.
    Dizbay M; Altuncekic A; Sezer BE; Ozdemir K; Arman D
    Int J Antimicrob Agents; 2008 Jul; 32(1):29-32. PubMed ID: 18539006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antimicrobial susceptibility of extended-spectrum beta-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial.
    Hoban DJ; Bouchillon SK; Dowzicky MJ
    Diagn Microbiol Infect Dis; 2007 Apr; 57(4):423-8. PubMed ID: 17403448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isolation of uncommon respiratory and enteric Acinetobacter baumannii from hematologic patients and emergence of tigecycline-resistance.
    Savini V; Catavitello C; Pompetti F; Talia M; Costanzi L; Balbinot A; Febbo F; Di Zacomo S; Esattore F; D'Antonio D
    J Infect; 2008 Dec; 57(6):497-500. PubMed ID: 19027170
    [No Abstract]   [Full Text] [Related]  

  • 25. In vitro synergistic activity of tigecycline and colistin against XDR-Acinetobacter baumannii.
    Dizbay M; Tozlu DK; Cirak MY; Isik Y; Ozdemir K; Arman D
    J Antibiot (Tokyo); 2010 Feb; 63(2):51-3. PubMed ID: 19942947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of tigecycline against colistin-resistant Acinetobacter spp. isolates from Korea.
    Park YK; Choi JY; Song JH; Ko KS
    Int J Antimicrob Agents; 2009 Mar; 33(3):289-90. PubMed ID: 19091518
    [No Abstract]   [Full Text] [Related]  

  • 27. In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan determined by the broth microdilution and disk diffusion methods.
    Liao CH; Kung HC; Hsu GJ; Lu PL; Liu YC; Chen CM; Lee CM; Sun W; Jang TN; Chiang PC; Cheng YJ; Lin HC; Shi ZY; Wang LS; Chuang YC; Tsao SM; Lu CT; Liu JW; Huang CH; Hsueh PR
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S192-6. PubMed ID: 19013354
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Flamm RK; Shortridge D; Castanheira M; Sader HS; Pfaller MA
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii.
    Schafer JJ; Goff DA; Stevenson KB; Mangino JE
    Pharmacotherapy; 2007 Jul; 27(7):980-7. PubMed ID: 17594203
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus-Acinetobacter baumannii complex.
    Ruzin A; Keeney D; Bradford PA
    J Antimicrob Chemother; 2007 May; 59(5):1001-4. PubMed ID: 17363424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of tigecycline against Acinetobacter baumannii isolates from a teaching hospital in Malaysia.
    Dhabaan GN; AbuBakar S; Shorman MA; Hassan H
    J Chemother; 2012 Apr; 24(2):87-92. PubMed ID: 22546763
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutant prevention concentration of tigecycline for Acinetobacter baumannii and Klebsiella pneumoniae clinical isolates.
    Choi MJ; Peck KR; Ko KS
    J Antimicrob Chemother; 2015 Feb; 70(2):621-2. PubMed ID: 25304645
    [No Abstract]   [Full Text] [Related]  

  • 33. Tigecycline minimum inhibitory concentration for carbapenem-resistant Acinetobacter baumannii by two methods.
    Wang R; Wang H; She D
    Chin Med J (Engl); 2014; 127(10):1997. PubMed ID: 24824274
    [No Abstract]   [Full Text] [Related]  

  • 34. Prevalence of colistin and tigecycline resistance in Acinetobacter baumannii clinical isolates from 2 hospitals in Riyadh Region over a 2-year period.
    Baadani AM; Thawadi SI; El-Khizzi NA; Omrani AS
    Saudi Med J; 2013 Mar; 34(3):248-53. PubMed ID: 23475088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative in vitro activities of tigecycline (GAR-936) and other antimicrobial agents against Stenotrophomonas maltophilia.
    Betriu C; Rodríguez-Avial I; Sánchez BA; Gómez M; Picazo JJ
    J Antimicrob Chemother; 2002 Nov; 50(5):758-9. PubMed ID: 12407139
    [No Abstract]   [Full Text] [Related]  

  • 36. Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
    Peleg AY; Adams J; Paterson DL
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2065-9. PubMed ID: 17420217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of tigecycline in the control of a carbapenem-resistant Acinetobacter baumannii outbreak in an intensive care unit.
    Jamal W; Salama M; Dehrab N; Al Hashem G; Shahin M; Rotimi VO
    J Hosp Infect; 2009 Jul; 72(3):234-42. PubMed ID: 19493588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trends in the susceptibility of U.S.
    Pfaller MA; Shortridge D; Carvalhaes CG; Castanheira M
    Microbiol Spectr; 2023 Dec; 11(6):e0198123. PubMed ID: 37921464
    [No Abstract]   [Full Text] [Related]  

  • 40. Optimizing therapy for Acinetobacter baumannii.
    Peleg AY
    Semin Respir Crit Care Med; 2007 Dec; 28(6):662-71. PubMed ID: 18095230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.